Introduction

C
ancers of the head and neck are the sixth most common cancer type worldwide and account for nearly 2.3 % of all cancers in the USA [1, 2] . Oral squamous cell carcinoma (SCC) represents approximately 90 % of cancerous lesions that develop in the oral cavity and is often associated with poor prognosis due to advanced stage of presentation, local and regional recurrence and the possibility of multiple primary tumors due to field cancerization from carcinogen exposure [3] [4] [5] . Despite advances in imaging, surgery and multimodality therapy, there has been only modest improvement of approximately 15 % in survival over the past 50 years. Globally, the 5-year survival rate is 60 % [6] . Tobacco use and alcohol consumption are often associated with the development of oral SCC; however, infection with certain strains of human papilloma virus is rapidly becoming a major cause of this disease, especially in the oropharynx [7, 8] .
Oral SCC is a debilitating disease often associated with detrimental impact on quality of life. However, early detection and treatment may reduce the side effects of the disease and improve prognosis. Unfortunately, only 30-40 % of oral SCC patients present with early stage disease [9] . Many patients do not have symptoms or present to their physician until their lesions are large and advanced.
Traditional detection and staging of oral SCC includes directed biopsies after physical examination, endoscopy, and imaging studies such as computed tomography (CT), magnetic resonance (MRI), and positron emission tomography (PET) with 2-deoxy-2-[ 18 
F]fluoro-D-glucose (
18 F-FDG) [10] . However, each imaging technique has limitations, especially in resolution and the sensitivity to detect small lesions.
There is a critical need to develop novel imaging technologies and therapeutics to detect and treat cancers at an early stage. Superficial lesions are notoriously difficult to image with CT or MRI. 18 F-FDG PET in the head and neck is typically described as demonstrating the capability to detect tumors of 1 cm 3 in volume, although the detection limit varies depending upon the metabolic uptake of the tumor [11] . Additionally, the high glucose utilization of the tonsillar tissue in the pharynx may complicate the image analysis of adjacent structures. Centers such as ours that perform large volumes of skull base surgery have experienced challenges with traditional 18 F-FDG PET imaging of tumors of the sinonasal tract, nasopharynx, and skull base due to their proximity to the high glucose-utilizing tissue of the brain. Due to its high sensitivity, PET has the potential to detect small lesions in regions with low background activity. While 18 F-FDG is the gold standard radiotracer for clinical use, novel tracers such as 64 Cu-liposomes possess characteristics that may be beneficial in this patient population. 64 Cu-liposomes are unique and multifunctional as they can act as a radiotracer probe for cancerous lesions, can be used as a method to assess the accumulation of nanoparticles within lesions, and can be used as a vehicle for targeted drug delivery.
64 Cu-liposomes have been utilized for PET imaging in preclinical models of breast cancer and cardiovascular disease [12] [13] [14] [15] [16] [17] . 64 Cu has a 12.7-h half-life and can be conjugated to 100-nm liposomes [13, 14] . These nanoparticles are excluded in normal tissues based on vascular permeability, but malignant tumors disproportionately accumulate these liposomes based on the enhanced permeability and retention effect [18] . The ability to conjugate specific targeting ligands to the liposome surface and to enclose therapeutic drugs within the particle facilitates their use both as an imaging agent and a potential targeted therapeutic agent [19] . Previous studies have validated the liposomal distribution obtained by PET imaging with optical microscopy using the liposomal core to carry the fluorescent tracer or by comparison with other large tracers such as albumin [12, 15, 16, 20] .
The hamster model of head and neck cancer has been shown to be an effective model of the transition from premalignant to fully malignant lesions [5, 21, 22] . In this study, we compare PET imaging with 64 Cu-liposomes and 18 F-FDG to assess the future potential for imaging and drug delivery in the established hamster model of oral SCC across all pathologic stages from early precancerous lesions to carcinoma. We set out to determine if 64 Cu-liposomes would accumulate in precancerous lesions as well as in invasive oral SCC of the head and neck.
Materials and Methods
Overview of the Study
In total, four treatment groups (six animals in each group, Table 1) were studied. Two groups were imaged 5-8 weeks after the start of 7,12-dimethylbenz[a]anthracene (DMBA) application, representing early precancerous lesions. Another two groups were imaged between 12 and 22 weeks after the start of DMBA application, representing late, pathologically advanced lesions. In each pair of groups, DMBA application was halted 1 to 2 weeks prior to PET in one cohort.
For each animal, PET images were acquired with both 18 F-FDG and 64 Cu-liposomes (Supplemental Fig. 1 ), within 1 week of each other. After the last PET time point, cheek pouches were harvested and sent for histological analysis. Margin-marking dye was placed on the sample after harvest and was used to determine orientation of histology samples for better correlation with PET images.
Tumor Induction
All animal experiments were conducted under a protocol approved by the University of California, Davis, Animal Care and Use Committee (Davis, CA). Four to five week-old male golden Syrian hamsters (Harlan, Indianapolis, IN) weighing~150 g were studied due to the large buccal mucosa surface area and the well-established protocol for inducing squamous neoplasms [23] . In addition, DMBA-induced tumors follow the pathological changes associated with human oral cavity tumors [24] . Animals were housed in a temperature-controlled room in ventilated cages and maintained on a 12-h day/night cycle with animal diet and water provided ad libitum. Tumors were induced in the buccal pouch by topical application of 20 μl of 0.5 or 2.5 % (grams per milliliter) of the DMBA (Sigma-Aldrich, St. Louis, MI) in mineral oil three times a week for 5-22 weeks. Animals received DMBA applications either bilaterally (right and left cheek pouches) or unilaterally (right cheek pouch only). In an effort to control for inflammation and its potential for false-positive scans, DMBA application was stopped for up to 2 weeks prior to PET imaging in a subset of cases.
Lesion Grading by Gross Examination of Mucosa
Throughout the DMBA application process, animals were visually inspected weekly for signs of mucosal change (Supplemental Fig. 2 ). Animals were classified as having early precancerous lesions when gross examination of the mucosa showed reddened, thick, and scaly patches, characteristic of hyperkeratosis. White and raised lesions less than 1 mm in diameter were also included in the precancerous group and were generally observed early in the DMBA application process of 5-8 weeks. Raised, reddened lesions 92 mm in diameter were classified as late, more pathologically advanced lesions. These were generally observed at ∼12-21 weeks after the start of DMBA application.
Synthesis of the Radioactive Tracers
F-FDG and
64 CuCl 2 were purchased from PETNET (PETNET Solutions, Sacramento, CA) and MIR Radiological Science at Washington University Medical School (St. Louis, MI), respectively, under a protocol controlled by the University of California, Davis.
64 Cu-liposome preparation followed a previously reported method [13] . All lipids and a mini-extruder were purchased from Avanti Polar Lipids (Alabaster, AL). In brief, lipids (approximately 25 mg, HSPC/cholesterol/DSPE-PEG2K-OMe/6-BAT-PEG-lipid = 55.5:39:5.0:0.5, mol/mol/mol/mol) in chloroform were added to a glass test tube. The solvent was evaporated by gently blowing nitrogen gas under a low spinning vortexer to create a thin film. After additional drying for at least 4 h in the lyophilizer, lipids were resuspended in 0.1 M ammonium citrate buffer (0.4 ml, pH 5.5), and a glass test tube was then incubated in the water bath for 5-10 min at 60°C. The milky solution was drawn into the syringe and extruded 21 times through a 100-nm membrane filter (Whatman, NJ) on a 60-62°C heating block. After cooling to room temperature, 64 Cu (18.5 MBq/3 mg total lipids) was added to the liposomes in 0.1 M ammonium citrate (0.1 ml) buffer. After incubation at 30°C for 1 h, 0.1 M EDTA (20 μl) was added and incubated for 10 min in order to remove nonspecifically bound 64 Cu.
64
Cu-liposomes were purified using a size exclusion column filled with G75 in PBS (1×). The radiochemical purity of liposomes on TLC was more than 95 %. Averaged specific activity through several studies was 5.7±0.5 MBq/mg.
PET Imaging
All PET images were obtained on a microPET-Focus 120 (Siemens Medical Solutions, USA, Inc.). Each group of animals underwent 18 F-FDG and 64 Cu-liposome PET imaging during the same week or within 1 week of each other.
F-FDG Protocol
The animals were anesthetized with 2-3 % isoflurane, and 18 F-FDG was administered by intravenous (IV) injection. After 30 min, the animals were again anesthetized with 2-3 % isoflurane and placed individually in the supine position on the PET scanner bed. Static PET scans were then obtained for 30 min. 
Cu-liposome Protocol
Animals were anesthetized with 2-3 % isoflurane and placed individually in the supine position on the scanner bed. Thirtyminute PET acquisitions were started immediately after IV injection of the 64 Cu-liposomes and again at 24 h postinjection.
Image Analysis
Images were obtained using the ASI Pro Virtual Machine Software (CTI Molecular Imaging), reconstructed using a maximum a posteriori algorithm, and quantified with ASI Pro by defining regions of interest (ROI) and calculating the percent injected dose per cubic centimeter (%ID/cc) within the ROIs. 
Histopathology Examination and Lesion Grading
After the last time point of PET imaging, the animals were euthanized, and the cheek pouches were removed, fixed overnight in 10 % formalin and then placed in 70 % ethanol. After fixation, tumors were processed with a Tissue Tek VIP then paraffin embedded using a Tissue Tek TEC (Sakura Finetek, Torrance, CA, USA). Four-micron slices were cut using a manual rotary microtome (Leica RM2235, Leica Microsystems Inc., Bannockburn, IL USA) and stained with hematoxylin and eosin. All samples were examined by a pathologist blinded to the study. Tissue sections were evaluated for oral epithelial dysplasia based on the presence of architectural and cytological changes according to the WHO classification [25] . Lesions were subclassified into one of four categories including mild dysplasia (MD), severe dysplasia (SD), carcinoma in situ (CIS), and SCC. MD demonstrates proliferation of cells of the basal and parabasal layers which do not extend beyond the lower third of the epithelium. Cytological atypia is generally mild, and mitoses, when present, are usually basally located and normal. Architectural changes are minimal. In SD, there is an abnormal proliferation extending from the basal layer into the upper third of the epithelium. Cytological and architectural changes can be very prominent. CIS is characterized by full-thickness cytological and architectural changes. Cases were classified as SCC when there was invasion into the underlying connective tissue.
The degree of acute inflammation in each sample was also evaluated in the stromal area adjacent to the lesion. Acute inflammatory cells (PMNs) were counted at 40× magnification, and the degree of inflammation was scored as either 0, 1+, 2+ or 3+ based on counting either 0, 1-10, 11-20 or more than 20 inflammatory cells, respectively. Areas selected for counting of PMNs were limited to the stroma underlining the lesion and were devoid of necrosis or cellular degeneration. We avoided counting the PMNs in areas adjacent to ulcerated lesions.
Statistical Analysis
All statistical analyses were performed using software: Excel 11.0 (Microsoft, Seattle, WA), and MiniTab 16 (Minitab Inc., State College, PA). Data were recorded as a mean ± standard deviation for continuous data. Significant differences were assessed using a two-tailed Student's t test (for individual comparisons) and ANOVA (for multiple comparisons), with a P value less than 0.05 indicating a statistically significant difference.
Results
Pathological grade and corresponding level of inflammation were assessed from histopathology samples across all animal groups (Fig. 1) . This model reliably produced pathologies ranging from MD to SCC. Lesions graded as pathologically normal and those reflective of MD were found only in early lesion groups that received DMBA application for 5 or 8 weeks, while more pathologically advanced lesions graded as SD, CIS, and SCC were found in groups that were treated with DMBA for a longer time period. Highest levels of inflammation (3+) were observed in lesions graded as SCC, while all other pathology grades had inflammation levels ranging from 0 to 2+.
Unilateral, right-sided DMBA application resulted in tumors in the right cheek pouch only, showing no evidence of pathology on the contralateral cheek pouch that did not receive DMBA treatment (Fig. 2a) . In these animals, the untreated left side served as an internal normal mucosal control. Bilateral DMBA application resulted in bilateral tumors confirmed by PET images and histopathology of tissue sections (data not shown). Lesions observed in the PET images were compared with their corresponding histopathology in panels b, c, d, and e of Fig. 2 Culiposome imaging at 0 and 24 h demonstrate the differences between the tracers and differences between the treated and untreated animals for each of the four DMBA-treated groups (Fig. 3) . The images are normalized to the blood signal for 64 Cu-liposomes and to the heart muscle for 18 F-FDG PET scans in order to improve visualization. No lesions were detected in images obtained with either radioisotope in the untreated animal (column a). Groups that received DMBA application for 5 and 8 weeks had lesions classified as early precancerous lesions and were pathologically graded as normal to MD. Figure 3 shows an example of one animal from each of the 5-week (column b) and 8-week (column c) DMBA-treated groups. In these two animals, lesions are clearly visualized at 24 h post-64 Cu-liposome injection (arrows) and are not visible following imaging with 18 F-FDG. A subset of early lesions graded as MD within these two groups (4 lesions/18 cheek pouches) were detected only with 64 Cu-liposome imaging at 24 h postinjection and were not detected with 18 F-FDG (images not shown). Groups that received DMBA application for 22 weeks (column d) and 12 weeks (column e) have lesions classified as late pathologically advanced lesions graded from normal to SCC (normal grades are from untreated control animals or untreated 64 Cu-liposomes circulated stably within the blood pool (Fig. 4) . Across all animals, the average circulating activity decreased from 10.2±2.4 %ID/cc at the time of the injection to (Fig. 5a) . At 24 h postinjection (approximately corresponding to the peak accumulation), 64 Cu-liposome activity exceeded the averaged accumulation at the 30-min time point (peak accumulation) of 18 F-FDG (1.4±0.8 %ID/cc) (PG0.001). A similar trend was observed within each individual group (Fig. 5b) ; the accumulation of performed between the cases where DMBA was stopped before PET imaging and the cases where DMBA was not stopped (Fig. 5c) . No significance was reached for each radioisotope, suggesting that 18 F-FDG and 64 Cu-liposome accumulation was not significantly altered by stopping DMBA application before PET. Also, 64 Cu-liposome accumulation was similar in lesions graded as low inflammation (0-1) and high inflammation (2-3) (Fig. 5c) .
Tumor ROIs were then grouped according to their graded histopathology categories (Fig. 5d) . As the disease progressed from normal (no treatment contralateral control) to SCC, the accumulation of both radiotracers increased: The lesion-to-brain ratio also demonstrated improved imaging characteristics for 64 Cu-liposomes (Fig. 6a, b) , compared with 18 F-FDG. When grouped according to DMBA application pattern (Fig. 6a) , the lesion-to-brain ratio of 18 F-FDG (0.2±0.1 to 1.0±0.7) was significantly lower than that of 64 Cu-liposomes at 24 h after injection (4.9±2.1 to 7.1±1.1; PG 0.001) in each group. When grouped according to the lesion histopathology (Fig. 6b) , the lesion-to-brain ratios increased with the progress of the lesion from normal tissue to SCC for Similarly, the lesion-to-cheek pouch background ratio was calculated as a measurement of imaging sensitivity (Fig. 6c, d) . 64 Cu-liposome accumulation at 24 h postinjection ranged from 7.1±3.4 to 15.4±7.6, while 18 F-FDG accumulation ranged from 3.0±1.4 to 7.0±1.6 (PG0.05, except the 12-week 2.5 % treatment group). When grouped according to their graded histopathology 
Discussion
Early detection of neoplasms offers the potential for higher cure rates and decreased treatment-related morbidity. Taken together, our data demonstrate the increased sensitivity of 64 Cu-liposomes for detecting abnormal mucosa and the potential to improve the detection of early tumors compared to 18 F-FDG, which typically has a 1-cm 3 size limit for detection. While we have demonstrated that the accumulation is not restricted to neoplasms, the greater sensitivity of 64 Cu-liposomes improves our ability to detect early dysplastic or preneoplastic lesions not visualized on 18 F-FDG images. By detecting abnormal tissue earlier, treating physicians will be alerted to high-risk areas allowing earlier biopsy and management. This increased sensitivity occurs at the expense of specificity for malignancies. Sampled tissue showing mild mucosal changes (histologically normal and mild dysplasia) demonstrated increased 64 Cu-liposome uptake compared to nontreated adjacent tissue. There are several possible explanations for this finding. Topical application of the DMBA carcinogen in this model leads to tissue changes including inflammation in advance of neoplastic transformation [26] . This inflammation results in leaky capillaries allowing the liposomes to exit the vasculature and accumulate in the tissues [27] . Our finding that a period without carcinogen exposure prior to imaging did not influence radiotracer accumulation would suggest that this is unlikely to be the sole explanation. Another possibility is that we are detecting neoplastic transformation before a definitive histopathological diagnosis can be determined. This is an interesting and important possibility as oral cancers and head and neck neoplasms are often associated with large field carcinogen exposure from tobacco smoke and alcohol ingestion [28] . After appropriate surgical resection, it is not uncommon for second malignancies to develop despite negative surgical margins by histopathology. Genetic analysis of adjacent histologically "normal" tissue has demonstrated mutations well beyond the cleared margins of the tumor [29] . Therefore, we may be imaging preneoplastic transformations with 64 Cu-liposomes earlier than the lesions would be detected with traditional histopathology. Future studies analyzing the genetic alterations found in 64 Cu-liposome-positive, histopathologically normal lesions would help to answer this question.
An additional advantage of 64 Cu-liposomes compared to 18 F-FDG is the dramatically increased lesion-to-brain ratio. While pure skull base tumors are rare, tumors of the oral cavity and pharynx may extend to the skull base and travel along nerves toward the brain. While MRI and CT imaging provide excellent anatomical imaging, postradiation edema and scarring can be difficult to distinguish from recurrent tumor. As such, functional imaging is often a useful adjunct to evaluate these lesions. As the brain is an obligate glucosemetabolizing organ, decreasing the brain background by using an alternative tracer to the glucose analog FDG dramatically improves the lesion detection with PET imaging in this anatomic location, offering the potential to increase both sensitivity and specificity in imaging tumors near the brain. Similarly, the tonsillar tissue in the oropharynx may have a high glucose uptake and background FDG accumulation. 64 Cu-liposomes may also improve our imaging of lesions in this critical area as well.
Beyond the use of 64 Cu-liposomes for lesion detection, the results presented here demonstrate the opportunity for liposomal drug delivery in such lesions. Our radiolabeling technique allows for the facile labeling of liposomes that contain a therapeutic cargo, and we have previously demonstrated that for a stable liposomal formulation, the biodistribution of the radioactive liposomal shell is similar to that of the liposomal cargo [13, 20, 30] . The accumulation of 64 Cu-liposomes (%ID/ cc) was significantly higher at 24 h than with 18 F-FDG, where an accumulation of 2.6-4.14 %ID/cc of 64 Cu-liposomes was observed in lesions in this study. This compares favorably to other studies of radiotracer accumulation in similar-sized animal models, and demonstrates the possibility of utilizing this model to study drug delivery to head and neck tumors in the future [31] . The selective accumulation in these tumors allows for dramatic improvement in the therapeutic ratio of drug delivery to the tumor compared to drug delivery to normal tissues. While we did observe enhanced accumulation in both cancerous and precancerous tissues, the opportunity to concentrate therapeutics in early lesions may prove valuable in cancers that have a high likelihood of local recurrence. In such cancers, a combination of precancer and advanced disease exists simultaneously, and such early treatment may reduce progression. More importantly, it offers the potential to increase the therapeutic efficacy while minimizing systemic toxicity. Future studies will address the application of this concept.
Conclusion
64 Cu-liposomes accumulate in abnormal mucosa in the hamster DMBA-induced oral carcinogenesis model. When compared to traditional 18 F-FDG PET, 64 Cu-liposomes demonstrated increased sensitivity and earlier detection. Specificity to cancer was reduced in this model with early, histologically normal and dysplastic lesions being identified as well. Accumulation of the 64 Cu-liposomes was significant and offers the potential for both novel imaging and therapeutic applications of this tracer.
